Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

NCT05193578 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

154

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia
Prediabetic State

Interventions

DRUG: Semaglutide, 1.34 mg/mL
OTHER: Placebo

Sponsor

Jan Frystyk

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]